News & Updates
Filter by Specialty:
Mevrometostat plus enzalutamide improves outcomes in mCRPC patients
Treatment with mevrometostat (MEV), an enhancer of zeste homolog 2 inhibitor, in combination with enzalutamide (ENZ) results in better survival outcomes and response than ENZ alone among patients with metastatic castration-resistant prostate cancer (mCRPC), reports a study presented at ASCO GU 2025. The combined therapy also demonstrates a favourable safety profile.
Mevrometostat plus enzalutamide improves outcomes in mCRPC patients
27 Feb 2025
First-line nivolumab-ipilimumab therapy extends survival in unresected HCC
Treatment with nivolumab plus ipilimumab in the frontline setting provides clinically meaningful overall survival (OS) benefit compared with lenvatinib or sorafenib to patients with unresectable hepatocellular carcinoma (HCC) who were naive to systemic therapy, according to data from the phase III CheckMate 9DW study presented at ASCO GI 2025.
First-line nivolumab-ipilimumab therapy extends survival in unresected HCC
25 Feb 2025
Aspirin use lowers risk of common GI cancers
Taking aspirin contributes to a reduced risk of several gastrointestinal (GI) malignancies, such as colorectal cancer (CRC), liver cancer, stomach cancer, and pancreatic cancer, as shown by the results of a 20-year study presented at ASCO GI 2025. However, no association is seen with most non-GI cancers.
Aspirin use lowers risk of common GI cancers
24 Feb 2025
Can sintilimab maintain or improve HRQoL in 1L treatment of NSCLC?
Addition of sintilimab to pemetrexed and platinum-based chemotherapy maintained or improved health-related quality of life (HRQoL) and symptoms compared with chemotherapy alone in first-line (1L) treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), according to a prespecified exploratory analysis of the phase III ORIENT-11 trial.
